Fig. 4From: Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trialChanges from baseline in NYHA class at week 24 in subgroups stratified by baseline median serum insulin concentrations (left) and HOMA-IR (right). The numbers next to the bars indicate the frequency of cases in which NYHA improved or worsened at week 24. Between-subgroup differences in the treatment effect on NYHA class are analyzed as Pfor interaction. HOMA-IR, homeostasis model assessment of insulin resistance; NYHA, New York Heart AssociationBack to article page